Global Human Microbiome Therapeutics Market 2023-2027

Description

List of Tables

The human microbiome therapeutics market is forecasted to grow by USD 732.95 mn during 2022-2027, accelerating at a CAGR of 30.11% during the forecast period. The report on the human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of chronic diseases, robust pipeline in human microbiome therapeutics market, and side effects of existing treatments for heath disorders.

Technavio's human microbiome therapeutics market is segmented as below:

By Product

Probiotics
Prebiotics
Medical foods
Prescription drugs

By Application

Gastrointestinal disorders
Infectious diseases
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increase in industry-academia collaboration for development of novel therapeutics as one of the prime reasons driving the human microbiome therapeutics market growth during the next few years. Also, increasing investments in human microbiome therapeutics and increasing partnerships in human microbiome therapeutics market will lead to sizable demand in the market.

The report on the human microbiome therapeutics market covers the following areas:

Human microbiome therapeutics market sizing
Human microbiome therapeutics market forecast
Human microbiome therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include 4D pharma Plc, BiomX Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc., Evogene Ltd., Ferring BV, Finch Therapeutics Group Inc., Flightpath Biosciences, Johnson and Johnson Services Inc., MaaT Pharma, Microbiotica Ltd., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., YSOPIA Bioscience, and Locus Biosciences Inc.. Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR43730

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global human microbiome therapeutics market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global human microbiome therapeutics market 2017 - 2021 ($ million)
4.2 Product Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
4.3 Application Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

6.1 Market segments
Exhibit 30: Chart on Product - Market share 2022-2027 (%)
Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Probiotics - Market size and forecast 2022-2027
Exhibit 34: Chart on Probiotics - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Probiotics - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Probiotics - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Probiotics - Year-over-year growth 2022-2027 (%)
6.4 Prebiotics - Market size and forecast 2022-2027
Exhibit 38: Chart on Prebiotics - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Prebiotics - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Prebiotics - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Prebiotics - Year-over-year growth 2022-2027 (%)
6.5 Medical foods - Market size and forecast 2022-2027
Exhibit 42: Chart on Medical foods - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on Medical foods - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on Medical foods - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Medical foods - Year-over-year growth 2022-2027 (%)
6.6 Prescription drugs - Market size and forecast 2022-2027
Exhibit 46: Chart on Prescription drugs - Market size and forecast 2022-2027 ($ million)
Exhibit 47: Data Table on Prescription drugs - Market size and forecast 2022-2027 ($ million)
Exhibit 48: Chart on Prescription drugs - Year-over-year growth 2022-2027 (%)
Exhibit 49: Data Table on Prescription drugs - Year-over-year growth 2022-2027 (%)
6.7 Market opportunity by Product
Exhibit 50: Market opportunity by Product ($ million)
Exhibit 51: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Application

7.1 Market segments
Exhibit 52: Chart on Application - Market share 2022-2027 (%)
Exhibit 53: Data Table on Application - Market share 2022-2027 (%)
7.2 Comparison by Application
Exhibit 54: Chart on Comparison by Application
Exhibit 55: Data Table on Comparison by Application
7.3 Gastrointestinal disorders - Market size and forecast 2022-2027
Exhibit 56: Chart on Gastrointestinal disorders - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Gastrointestinal disorders - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Gastrointestinal disorders - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Gastrointestinal disorders - Year-over-year growth 2022-2027 (%)
7.4 Infectious diseases - Market size and forecast 2022-2027
Exhibit 60: Chart on Infectious diseases - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Infectious diseases - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Infectious diseases - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Infectious diseases - Year-over-year growth 2022-2027 (%)
7.5 Others - Market size and forecast 2022-2027
Exhibit 64: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 65: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 66: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 67: Data Table on Others - Year-over-year growth 2022-2027 (%)
7.6 Market opportunity by Application
Exhibit 68: Market opportunity by Application ($ million)
Exhibit 69: Data Table on Market opportunity by Application ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 France - Market size and forecast 2022-2027
Exhibit 99: Chart on France - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on France - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on France - Year-over-year growth 2022-2027 (%)
9.10 UK - Market size and forecast 2022-2027
Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.11 Japan - Market size and forecast 2022-2027
Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ million)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 4D pharma Plc
Exhibit 119: 4D pharma Plc - Overview
Exhibit 120: 4D pharma Plc - Product / Service
Exhibit 121: 4D pharma Plc - Key offerings
12.4 BiomX Inc.
Exhibit 122: BiomX Inc. - Overview
Exhibit 123: BiomX Inc. - Product / Service
Exhibit 124: BiomX Inc. - Key offerings
12.5 Eligo Bioscience
Exhibit 125: Eligo Bioscience - Overview
Exhibit 126: Eligo Bioscience - Product / Service
Exhibit 127: Eligo Bioscience - Key offerings
12.6 ENTEROME SA
Exhibit 128: ENTEROME SA - Overview
Exhibit 129: ENTEROME SA - Product / Service
Exhibit 130: ENTEROME SA - Key offerings
12.7 Evelo Biosciences Inc.
Exhibit 131: Evelo Biosciences Inc. - Overview
Exhibit 132: Evelo Biosciences Inc. - Product / Service
Exhibit 133: Evelo Biosciences Inc. - Key offerings
12.8 Evogene Ltd.
Exhibit 134: Evogene Ltd. - Overview
Exhibit 135: Evogene Ltd. - Business segments
Exhibit 136: Evogene Ltd. - Key offerings
Exhibit 137: Evogene Ltd. - Segment focus
12.9 Ferring BV
Exhibit 138: Ferring BV - Overview
Exhibit 139: Ferring BV - Product / Service
Exhibit 140: Ferring BV - Key offerings
12.10 Finch Therapeutics Group Inc.
Exhibit 141: Finch Therapeutics Group Inc. - Overview
Exhibit 142: Finch Therapeutics Group Inc. - Product / Service
Exhibit 143: Finch Therapeutics Group Inc. - Key offerings
12.11 Johnson and Johnson Services Inc.
Exhibit 144: Johnson and Johnson Services Inc. - Overview
Exhibit 145: Johnson and Johnson Services Inc. - Business segments
Exhibit 146: Johnson and Johnson Services Inc. - Key news
Exhibit 147: Johnson and Johnson Services Inc. - Key offerings
Exhibit 148: Johnson and Johnson Services Inc. - Segment focus
12.12 OptiBiotix Health Plc
Exhibit 149: OptiBiotix Health Plc - Overview
Exhibit 150: OptiBiotix Health Plc - Product / Service
Exhibit 151: OptiBiotix Health Plc - Key offerings
12.13 PureTech Health Plc
Exhibit 152: PureTech Health Plc - Overview
Exhibit 153: PureTech Health Plc - Business segments
Exhibit 154: PureTech Health Plc - Key offerings
Exhibit 155: PureTech Health Plc - Segment focus
12.14 Second Genome Therapeutics
Exhibit 156: Second Genome Therapeutics - Overview
Exhibit 157: Second Genome Therapeutics - Product / Service
Exhibit 158: Second Genome Therapeutics - Key offerings
12.15 Seres Therapeutics Inc.
Exhibit 159: Seres Therapeutics Inc. - Overview
Exhibit 160: Seres Therapeutics Inc. - Product / Service
Exhibit 161: Seres Therapeutics Inc. - Key offerings
12.16 Synlogic Inc.
Exhibit 162: Synlogic Inc. - Overview
Exhibit 163: Synlogic Inc. - Product / Service
Exhibit 164: Synlogic Inc. - Key offerings
12.17 Takeda Pharmaceutical Co. Ltd.
Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 169: Inclusions checklist
Exhibit 170: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 171: Currency conversion rates for US$
13.4 Research methodology
Exhibit 172: Research methodology
Exhibit 173: Validation techniques employed for market sizing
Exhibit 174: Information sources
13.5 List of abbreviations
Exhibit 175: List of abbreviations